175 related articles for article (PubMed ID: 37723046)
21. Generation of diffuse intrinsic pontine glioma mouse models by brainstem-targeted in utero electroporation.
Patel SK; Hartley RM; Wei X; Furnish R; Escobar-Riquelme F; Bear H; Choi K; Fuller C; Phoenix TN
Neuro Oncol; 2020 Mar; 22(3):381-392. PubMed ID: 31638150
[TBL] [Abstract][Full Text] [Related]
22. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium.
Mueller S; Jain P; Liang WS; Kilburn L; Kline C; Gupta N; Panditharatna E; Magge SN; Zhang B; Zhu Y; Crawford JR; Banerjee A; Nazemi K; Packer RJ; Petritsch CK; Truffaux N; Roos A; Nasser S; Phillips JJ; Solomon D; Molinaro A; Waanders AJ; Byron SA; Berens ME; Kuhn J; Nazarian J; Prados M; Resnick AC
Int J Cancer; 2019 Oct; 145(7):1889-1901. PubMed ID: 30861105
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetic analysis of crizotinib in children with progressive/recurrent high-grade and diffuse intrinsic pontine gliomas.
Gibson EG; Campagne O; Selvo NS; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 2021 Dec; 88(6):1009-1020. PubMed ID: 34586478
[TBL] [Abstract][Full Text] [Related]
24. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
[TBL] [Abstract][Full Text] [Related]
25. ALK2 inhibitors display beneficial effects in preclinical models of
Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C
Commun Biol; 2019; 2():156. PubMed ID: 31098401
[TBL] [Abstract][Full Text] [Related]
26. Signal Transduction in Diffuse Intrinsic Pontine Glioma.
Duchatel RJ; Jackson ER; Alvaro F; Nixon B; Hondermarck H; Dun MD
Proteomics; 2019 Nov; 19(21-22):e1800479. PubMed ID: 31328874
[TBL] [Abstract][Full Text] [Related]
27. Microtubule-Targeting Combined with HDAC Inhibition Is a Novel Therapeutic Strategy for Diffuse Intrinsic Pontine Gliomas.
Ehteda A; Khan A; Rajakumar G; Vanniasinghe AS; Gopalakrishnan A; Liu J; Tsoli M; Ziegler DS
Mol Cancer Ther; 2023 Dec; 22(12):1413-1421. PubMed ID: 37683275
[TBL] [Abstract][Full Text] [Related]
28. Chorioallantoic membrane (CAM) assay to study treatment effects in diffuse intrinsic pontine glioma.
Power EA; Fernandez-Torres J; Zhang L; Yaun R; Lucien F; Daniels DJ
PLoS One; 2022; 17(2):e0263822. PubMed ID: 35157705
[TBL] [Abstract][Full Text] [Related]
29. Dimethyl alpha-ketoglutarate inhibits proliferation in diffuse intrinsic pontine glioma by reprogramming epigenetic and transcriptional networks.
Lee K; Yun S; Park J; Lee S; Carcaboso AM; Yi SJ; Kim K
Biochem Biophys Res Commun; 2023 Oct; 677():6-12. PubMed ID: 37523894
[TBL] [Abstract][Full Text] [Related]
30. A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets.
Zhu X; Lazow MA; Schafer A; Bartlett A; Senthil Kumar S; Mishra DK; Dexheimer P; DeWire M; Fuller C; Leach JL; Fouladi M; Drissi R
Acta Neuropathol Commun; 2021 Jan; 9(1):14. PubMed ID: 33431066
[TBL] [Abstract][Full Text] [Related]
31. Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma.
Cao H; Jin M; Gao M; Zhou H; Tao YJ; Skolnick J
Sci Rep; 2020 Apr; 10(1):6140. PubMed ID: 32273545
[TBL] [Abstract][Full Text] [Related]
32. Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma.
Wang D; Yan K; Yu H; Li H; Zhou W; Hong Y; Guo S; Wang Y; Xu C; Pan C; Tang Y; Liu N; Wu W; Zhang L; Xi Q
Cancer Res; 2024 Feb; 84(4):598-615. PubMed ID: 38095539
[TBL] [Abstract][Full Text] [Related]
33. MELK Inhibition in Diffuse Intrinsic Pontine Glioma.
Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E
Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363
[No Abstract] [Full Text] [Related]
34. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
Liao Y; Luo Z; Deng Y; Zhang F; Rao R; Wang J; Xu L; Kumar SS; Sengupta S; DeWire-Schottmiller M; Berry K; Garrett M; Fouladi M; Drissi R; Lu QR
Neuro Oncol; 2021 Jul; 23(7):1183-1196. PubMed ID: 33539525
[TBL] [Abstract][Full Text] [Related]
35. Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG.
Balakrishnan I; Danis E; Pierce A; Madhavan K; Wang D; Dahl N; Sanford B; Birks DK; Davidson N; Metselaar DS; Meel MH; Lemma R; Donson A; Vijmasi T; Katagi H; Sola I; Fosmire S; Alimova I; Steiner J; Gilani A; Hulleman E; Serkova NJ; Hashizume R; Hawkins C; Carcaboso AM; Gupta N; Monje M; Jabado N; Jones K; Foreman N; Green A; Vibhakar R; Venkataraman S
Cell Rep; 2020 Oct; 33(3):108286. PubMed ID: 33086074
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
[TBL] [Abstract][Full Text] [Related]
37. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
[TBL] [Abstract][Full Text] [Related]
38. Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas.
Dalle Ore C; Coleman C; Gupta N; Mueller S
Pediatr Neurosurg; 2023; 58(5):259-266. PubMed ID: 36642062
[TBL] [Abstract][Full Text] [Related]
39. Identification of new therapeutic targets and natural compounds against diffuse intrinsic pontine glioma (DIPG).
Chen J; Lin Z; Barrett L; Dai L; Qin Z
Bioorg Chem; 2020 Jun; 99():103847. PubMed ID: 32311581
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma.
Noll A; Myers C; Biery MC; Meechan M; Tahiri S; Rajendran A; Berens ME; Paine D; Byron S; Zhang J; Winter C; Pakiam F; Leary SES; Cole BL; Jackson ER; Dun MD; Foster JB; Evans MK; Pattwell SS; Olson JM; Vitanza NA
Neoplasia; 2023 Sep; 43():100921. PubMed ID: 37603953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]